Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Acetylation
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Drug Monitoring
Female
Gene Expression
Histone Deacetylase Inhibitors
/ administration & dosage
Histones
/ genetics
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute
/ diagnosis
Male
Middle Aged
Prognosis
Remission Induction
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
15
01
2019
revised:
15
04
2019
accepted:
28
05
2019
pubmed:
4
6
2019
medline:
20
8
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. We hypothesized that panobinostat prior to and during induction chemotherapy would be tolerable and augment response in patients showing increased histone acetylation. Patients received panobinostat 20-60 mg oral daily on days 1, 3, 5, and 8 with daunorubicin 60 mg/m Twenty-five patients ages 60-85 years (median age, 69) were treated. Fifteen patients had Panobinostat with "7+3" for older patients with AML was well tolerated. Panobinostat 50 mg on days 1, 3, 5, and 8 starting 2 days prior to "7+3" is recommended for future studies. Panobinostat-induced increases in histone acetylation in PBMCs predicted CR/CRi.
Identifiants
pubmed: 31152020
pii: 1078-0432.CCR-19-0171
doi: 10.1158/1078-0432.CCR-19-0171
doi:
Substances chimiques
Antineoplastic Agents
0
Histone Deacetylase Inhibitors
0
Histones
0
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4917-4923Informations de copyright
©2019 American Association for Cancer Research.